-
公开(公告)号：US20140045817A1
公开(公告)日：2014-02-13
申请号：US14057882
申请日：2013-10-18
申请人： Array BioPharma Inc.
发明人： Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Hicks , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao
IPC分类号： C07D471/04 , C07D451/06
CPC分类号： C07D471/04 , A61K31/437 , C07D451/06 , C07D519/00
摘要： Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
摘要翻译： 本文提供了一种在哺乳动物中治疗PIM-1和/或PIM-3和/或PIM-3激酶介导的病症的方法，其包括向所述哺乳动物施用治疗有效量的式I化合物：其中 A，B，R1，R1a，R2，R3，R4，R5，R6和R7具有说明书中给出的含义。
-
![SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS](/abs-image/US/2018/03/29/US20180086758A1/abs.jpg.150x150.jpg)
2.发明申请公开(公告)号：US20180086758A1
公开(公告)日：2018-03-29
申请号：US15717700
申请日：2017-09-27
申请人： ARRAY BIOPHARMA INC.
发明人： Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsäter , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
IPC分类号： C07D471/04 , A61K31/496 , A61K45/06
摘要： Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
-
公开(公告)号：US08987251B2
公开(公告)日：2015-03-24
申请号：US14057882
申请日：2013-10-18
申请人： Array BioPharma Inc.
发明人： Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Hicks , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao
IPC分类号： A61K31/437 , C07D471/04 , C07D451/06 , C07D519/00
CPC分类号： C07D471/04 , A61K31/437 , C07D451/06 , C07D519/00
摘要： Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
摘要翻译： 本文提供了一种在哺乳动物中治疗PIM-1和/或PIM-3和/或PIM-3激酶介导的病症的方法，其包括向所述哺乳动物施用治疗有效量的式I化合物：其中 A，B，R1，R1a，R2，R3，R4，R5，R6和R7具有说明书中给出的含义。
-
![Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors](/abs-image/US/2017/11/07/US09809590B2/abs.jpg.150x150.jpg)
公开(公告)号：US09809590B2
公开(公告)日：2017-11-07
申请号：US14858029
申请日：2015-09-18
申请人： Array BioPharma Inc.
发明人： Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
IPC分类号： C07D471/04 , A61K45/06 , A61K31/496
CPC分类号： C07D471/04 , A61K31/496 , A61K45/06
摘要： Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
-
![Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors](/abs-image/US/2020/06/02/US10669269B2/abs.jpg.150x150.jpg)
5.发明授权公开(公告)号：US10669269B2
公开(公告)日：2020-06-02
申请号：US15717700
申请日：2017-09-27
申请人： ARRAY BIOPHARMA INC.
发明人： Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsäter , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
IPC分类号： A61K31/496 , A61K45/06 , C07D471/04
摘要： Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
-
![SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS](/abs-image/US/2016/01/07/US20160002232A1/abs.jpg.150x150.jpg)
6.发明申请SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 有权取代的N-（1H-吲唑-4-基）咪唑并[1,2-a]吡啶-3-羧酰胺化合物作为III型受体酪氨酸激酶抑制剂公开(公告)号：US20160002232A1
公开(公告)日：2016-01-07
申请号：US14858029
申请日：2015-09-18
申请人： ARRAY BIOPHARMA INC.
发明人： Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
IPC分类号： C07D471/04 , A61K45/06 , A61K31/496
CPC分类号： C07D471/04 , A61K31/496 , A61K45/06
摘要： Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
摘要翻译： 用于治疗哺乳动物纤维化，骨相关疾病，癌症，自身免疫疾病，炎性疾病，心血管疾病，疼痛和灼伤的化合物。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.029 秒)
